Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.

Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ: MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors.

Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who discovered the team of scientific co-founders at UCLA and recognized the transformative potential of the science that ultimately evolved into eXoZymes.

Christopher Marlett, CEO of MDB Capital and a current board member of eXoZymes, will assume the role of Chairman to ensure the help and support that MDB Capital will continue to provide eXoZymes.

Michael Heltzen, CEO of eXoZymes, expressed his gratitude for Mo Hayat’s contributions, “Mo has been instrumental in guiding eXoZymes through critical milestones, including my transition to CEO and our successful public offering. On behalf of the entire team, I extend my deepest thanks to Mo for his dedication and getting the company off to a great venture journey.” Henceforth Michael Heltzen will serve as the President of eXoZymes Inc.

Christopher Marlett highlighted Mo Hayat’s ongoing role at MDB Capital, “Mo’s expertise in developing new companies has been invaluable to MDB’s mission of licensing transformative technologies and building them into successful enterprises. We look forward to Mo focusing his efforts toward launching new ventures under the MDB umbrella.

The leadership transition comes shortly after eXoZymes’ corporate rebranding from Invizyne Technologies and its ticker symbol change to “EXOZ” on February 12, 2025. These changes reflect the company’s commitment to advancing its innovative biomanufacturing platform.

About eXoZymes Inc.

Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature’s own processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new sustainable, scalable, and eco-friendly alternative: Exozymes.

Exozymes are advanced enzymes enhanced with AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions, that transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the logical successor to most SynBio projects. After SynBio, this pioneering technology enables entering the exozymes era of biotechnology.

Inspired by insights from four recent Nobel Prizes in Chemistry, this technological platform ushers in a paradigm shift in chemical production by introducing scalable and sustainable exozyme biosolutions.

While the company, eXoZymes Inc., has introduced “exozymes” (エキソザイム in Japanese katakana) as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.

Learn more on exozymes.com

Investor relations contact
Email: ir@exozymes.com

eXoZymes media contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

MDB Capital Holdings media contact
Email: media@mdb.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.